An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer

Abstract Dexamethasone has antitumor activity in metastatic castration resistant prostate cancer (mCRPC). We aimed to investigate intravenous liposome‐encapsulated dexamethasone disodium phosphate (liposomal dexamethasone) administration in mCRPC patients. In this exploratory first‐in‐man study, pat...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Josephina P. M. Vrouwe, Ingrid M. C. Kamerling, Michiel J. vanEsdonk, Josbert M. Metselaar, Frederik E. Stuurman, Gabri van derPluijm, Jacobus Burggraaf, Susanne Osanto
Format: article
Langue:EN
Publié: Wiley 2021
Sujets:
Accès en ligne:https://doaj.org/article/7f6f12eb65c74ad0b8cee9f1481033da
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!